June 29, 2015

Verseon Corporation (“Verseon” or the “Company”)

Annual Report for the Year Ended 31 December 2014

29 June 2015, Fremont, CA – Verseon Corporation (AIM: VSN, “Verseon” or “the Company”), a technology-based pharmaceutical company, today announces the publication of its Annual Report and Accounts for the twelve months ended 31 December 2014.

The report and accounts are available on the Company’s website (http://www.verseon.com/files/reports/verseon_ar_2014.pdf) and will be sent to shareholders upon request.

For further information please contact:

Verseon Corporation+1 (510) 225 9000
Adityo Prakash, Chief Executive Officer
Cenkos Securities (NOMAD and Broker)+44 (0) 20 7397 8900
Mark Connelly / Christopher Golden
FTI Consulting (PR Advisers)+44 (0) 20 3727 1000
Simon Conway / Robert Winder / Matthew Moss

Notes to Editors

About Verseon Corporation

Verseon is a pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. The Company is applying its platform to a growing drug pipeline and has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

Proprietary Platform

Consistently designs novel drug candidates that are unlikely to be found using conventional methods

 

Drug Programs

Three different therapeutic areas, all with unmet (or poorly met) medical needs